Skip to main content

Evofem Biosciences, Inc.

EVFM
Exchange
OTC
Industry
Pharmaceutical Preparations
SEC CIK
0001618835

No open-market purchases or sales by Evofem Biosciences, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Evofem Biosciences, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Evofem Biosciences, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Evofem Biosciences, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Zhang YanCFO0Jan 12, 20240
Kamdar Kim P.Director0Dec 22, 20230
Pelletier Saundra LChief Executive Officer186,722Apr 26, 20230
Greer GillianDirector–May 6, 20220
Rutherford ColinDirector–May 6, 20220
O'Brien Anthony StephenDirector–May 6, 20220
Rarick Lisa DaleDirector–May 6, 20220
Fitzpatrick Alexander AGeneral Counsel and Secretary516,422Feb 23, 20220
File Justin J.Chief Financial Officer810,982Feb 23, 20220
Barrans RussellChief Commercial Officer448,554Jul 9, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jan 12, 2024 (view filing)5:13 PM ETJan 12Same dayZhang YanCFOSSale−104$0.0385−$4−100.0%0 after
Dec 22, 2023 (view filing)Dec 211 dayKamdar Kim P.DirectorSSale−10$0.62−$6.2−100.0%0 after
May 31, 2022 (view filing)8:55 AM ETMay 274 daysPelletier Saundra LChief Executive OfficerPPurchase+141.0K$0.3525+$49.7K+147.3%236.7K after
Dec 20, 2021 (view filing)4:20 PM ETDec 20Same dayFitzpatrick Alexander AGeneral Counsel and SecretaryPPurchase+25.0K$0.389+$9.72K+8.0%336.4K after
Dec 20, 2021 (view filing)4:20 PM ETDec 20Same dayFile Justin J.Chief Financial OfficerPPurchase+40.6K$0.37+$15.0K+9.2%481.0K after
Dec 20, 2021 (view filing)4:19 PM ETDec 20Same dayPelletier Saundra LChief Executive OfficerPPurchase+135.0K$0.375+$50.6K+15.9%985.8K after